Pfizer Scientist Dies

Genetics researcher and senior vice president of the pharmaceutical giant, David Cox, has passed away unexpectedly at age 66.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, Montgomery County Planning CommissionThe head genetics researcher at Pfizer Corporation’s San Francisco office, David Cox, died unexpectedly, the company announced this week (January 22). He was 66 years old. Cox, a senior vice president who joined in the multinational pharmaceutical company in 2008, was considered a visionary leader in drug development and biotech innovations.

“David Cox was a world-renowned geneticist and a highly valued leader here at Pfizer,” a Pfizer spokeswoman said in a statement, reported by Forbes. “As the company’s lead geneticist based at our Rinat facility in San Francisco, David was a driving force in shaping Pfizer’s strategy on Precision Medicine, as well as our vision for the future of biomedical innovation. Our thoughts and sympathies are with David’s family during this difficult time, and he will be truly missed.”

Before joining Pfizer, Cox trained as a pediatrician and became professor of genetics and pediatrics at Stanford University as well as the co-director of the Stanford Genome Center. After being involved in the project to sequence the human genome, he went on to co-found and become the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Beth Marie Mole

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide